

Barr Laboratories, Inc.

2 Quaker Road • P.O. Box 2900 • Pomona, NY 10970-0519 • 845/362-1100

Citizen Petition

August 30, 2002

Dockets Management Branch
Food and Drug Administration (HFA-305)
5630 Fishers Lane Room 1061
Rockville, Maryland 20852

On behalf of the petitioner, Barr Laboratories, the undersigned submits this petition in quadruplicate pursuant to 21 CFR 10.30 and in accordance with the regulation at 21 CFR 314.161, requesting that the Commissioner of the Food and Drug Administration provide a determination whether a listed drug has been discontinued for reasons of safety or effectiveness.

A. Action Requested

The petitioner requests that the Commissioner of the Food and Drug Administration determine whether Ortho-Tri-Cyclen-21® (ethinyl estradiol; norgestimate 0.035 mg; 0.18 mg, 0.035 mg; 0.21 mg, 0.035 mg; 0.25 mg) tablets, NDA 19 697 sponsored by Ortho Mcneil Pharm., have been voluntarily discontinued from marketing or withheld from sale for reasons of safety or effectiveness.

B. Statement of Grounds

The publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, or Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. The List also identifies approved products that have never been marketed, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.

Ortho-Tri-Cyclen-21® (ethinyl estradiol; norgestimate 0.035 mg; 0.18 mg, 0.035 mg; 0.21 mg, 0.035 mg; 0.25 mg) tablets, NDA 19 697 sponsored by Ortho Mcneil Pharm., was approved by FDA on July 3, 1992. However, it is now listed in the discontinued section of the Orange Book. Therefore, because the NDA holder has discontinued marketing of this drug product, Barr Laboratories requests that the FDA determine whether Ortho Mcneil's decision to discontinue marketing Ortho-Tri-Cyclen-21® (ethinyl estradiol; norgestimate 0.035 mg; 0.18 mg, 0.035 mg; 0.21 mg, 0.035 mg; 0.25 mg) tablets was for reasons of safety or effectiveness.

02P 0392

CP 1

C. Environmental Impact

A claim for categorical exclusion of the requirement for submission of an environmental assessment is made pursuant to 21 CFR 25.31.

D. Economic Impact

Pursuant to 21 CFR 10.30(b), economic impact information is to be submitted only when requested by the Commissioner. This information will be provided is so requested.

E. Certification

The undersigned certifies that to the best of its knowledge and belief, the petition includes all information and views on which the petitioner relies, and that it includes representative data and information known to the petitioner that are unfavorable to the petition.

Sincerely,

A handwritten signature in black ink, appearing to read 'Nicholas Tantillo', with a stylized flourish at the end.

Nicholas Tantillo
Senior Director, Regulatory Affairs

Align top of FedEx PowerShip Label here.

ORIGIN ID PCTA (845) 348-8051
NICHOLAS TANTILLO
BARR LABORATORIES, INC
300 CORPORATE DRIVE
SUITE 100
BLAUVELT, NY 10913

SHIP DATE 30AUG02
SYSTEM #0624755 / CAFE2106
ACTUAL WGT 1 LBS MAN-WGT
ACCOUNT # 169872732

FedEx



FedEx Revenue Barcode

TO:

DOCKET MGT BRANCH
FDA (HFA-305)
5630 FISHERS LANE ROOM 10
ROCKVILLE, MD 20852

REF: 340



Delivery Address Barcode (FedEx-EDR)

PRIORITY OVERNIGHT

TRK#

4629 9752 5817 FORM 0201

TUE
Deliver by:
03SEP02
A2


20852

-MD-US

IAD

ZM GAIA

Pat # 156148 NRIT 12-01



he World On Ti

Align bottom of Peel and Stick Airbill here.

Select FedEx Letter or FedEx Envelope/Letter on your shipping document.